Why the study?
The ideal enoxaparin dosing weight metric remains unclear, as actual body weight may increase bleeding risk in obesity while ideal weight may result in underdosing.
Does dosing enoxaparin based on adjusted ideal or lean body weight improve the consistency of factor anti-Xa levels in hospitalized patients compared to actual body weight?
Does dosing enoxaparin based on adjusted ideal or lean body weight improve the consistency of factor anti-Xa levels in hospitalized patients compared to actual body weight?
In patients with obesity, calculating enoxaparin doses using ideal or lean body weight plus 40% may provide a more consistent factor anti-Xa response than using actual body weight.
Answers are grounded in this paper and cite their sources.
IBW +40% or LBW +40% may better align anti-Xa levels in obesity; leaves open need for prospective outcome trials before any practice change.
Aims The ideal dosing weight metric for enoxaparin remains elusive. Dosing remains focused on actual body weight, which may inadvertently increase the risk of bleeding in those with obesity, or ideal weight, which may underdose those with obesity. Our aim was to determine the optimal obesity‐adjusted enoxaparin dosing weight. Methods Multisite retrospective data were collected over a 2.0‐year period for those with minimum 48 h of in‐hospital twice‐daily enoxaparin and factor anti‐Xa level 3–5 h postdose ( n = 220). Multiple linear regression calculated the associated variance between a range of nominal dosing weights and factor anti‐Xa levels, adjusted for renal function. Dosing weights were calculated as ideal body weight (IBW) and then adjusted for increasing percentages of weight above IBW, i.e. IBW + 10% above IBW, IBW + 20% etc. up to actual body weight. A similar approach was used for lean body weight (LBW). Results For body mass index ≥30 kg/m 2 optimal variance explained by dosing weight metrics was at IBW + 40% (23%) and similarly for LBW + 40% (23%). Using actual body weight (ABW) had lowest associated variance with factor anti‐Xa levels (18%) followed by unadjusted IBW (13%) or unadjusted LBW (19%). In those with body mass index <30 kg/m 2 there was similar associated variance in the ranges of IBW + 20–50% and LBW 10–40% (21%). Conclusion Compared to IBW + 40% or LBW + 40% use of ABW to calculate dose was poorly associated with factor anti‐Xa levels, as was IBW or LBW. IBW + 40% and LBW + 40% require further study as a dosing weight metric and may provide a more consistent factor anti‐Xa response in those with obesity.
No takes yet. Share an insight, caveat, or question.
Roberts et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: